-67%

est. 2Y upside i

HealthcareSeries A

Using AI to help dementia patients age at home

Rank

#1115

Sector

Healthtech

Est. Liquidity

~4Y

Data Quality

Data: Medium

Craniometrix presents a strong upside opportunity driven by its rapid ARR growth ($4M in ~8 months) in the large and growing dementia care navigation market, bolstered by its proprietary AI and strategic partnerships.

Last updated: March 10, 2026

Bull (25%)+250%

Craniometrix leverages its proprietary CareGPT AI and early partnerships with Johns Hopkins and Arizona Neurology Associates to become the leading platform for Medicare's GUIDE program. Rapid expansion into new health systems drives ARR to $70M by 2028, justifying a $280M valuation at 3.5x current, attracting a strategic acquisition or a strong Series B round.

Base (50%)+75%

Craniometrix continues to grow steadily, expanding its reach within the dementia care navigation market and securing additional partnerships. ARR reaches $25M by 2028, leading to a $140M valuation, a solid 1.75x return from the current valuation, as it prepares for a Series B round.

Bear (25%)-75%

Slower-than-expected adoption of the Medicare GUIDE program and increased competitive pressure from large healthcare incumbents or well-funded startups limit Craniometrix's growth. ARR stalls at $10M, leading to a down round and a valuation of $20M, significantly eroding common stock value due to liquidation preferences.

Est. time to liquidity~4.0 years

Preference Stack Risk

high

Investors hold $21M in liquidation preferences ahead of common stock, representing 26.25% of the estimated current $80M valuation.

Dilution Risk

high

As a Series A company, Craniometrix will likely undergo at least one to two more significant funding rounds, leading to substantial future dilution for current equity holders.

Secondary Liquidity

none

There is currently no active secondary market for Craniometrix shares, and tender offers are unlikely at this early stage.

Questions to Ask at the Interview

Strategic questions based on Craniometrix's data — designed to show you've done your homework.

  • 1

    “Given the significant incumbent threat from large healthcare players like UnitedHealth and Epic, how is Craniometrix planning to maintain its competitive moat and prevent these giants from entering or dominating the dementia care navigation space, especially around the Medicare GUIDE program?”

  • 2

    “Craniometrix has achieved impressive ARR growth to $4M in a short period. What are the key drivers for scaling customer acquisition and expanding beyond initial partnerships, and what are the primary challenges you foresee in reaching $50M+ ARR within the next two years?”

  • 3

    “With $21M in total funding and a recent Series A, what is the company's projected runway, and what are the key milestones Craniometrix aims to achieve before its next funding round or a potential liquidity event for employees?”

Community

Valuation Sentiment

Our model estimates -67% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.